Laurus Labs Limited
LAURUSLABS.BO
Bombay Stock Exchange1,538.25
INR
+35.05
- -
Laurus Labs Limited
LAURUSLABS.BO
(Bombay Stock Exchange)
Recent
price
1,538.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Laurus Labs Limited, headquartered in Hyderabad, India, and founded in 2005, operates as a research-driven pharmaceutical and biotechnology company focused on developing and manufacturing active pharmaceutical ingredients (APIs), intermediates, generic formulations, finished dosage forms (FDF), and contract development and manufacturing organization (CDMO) services; it offers specialized solutions in anti-retroviral (ARV) drugs including Dolutegravir/lamivudine/tenofovir combinations, oncology and cardiovascular APIs, anti-diabetic therapies, proton pump inhibitors, central nervous system products, high-potent materials, veterinary APIs, agrochemicals, biologics via precision fermentation for nutraceuticals, dietary supplements, cosmetic products, alternative food proteins, and advanced modalities such as peptides, biocatalysis, flow chemistry, continuous hydrogenation, cell and gene therapies including CAR-T via subsidiary ImmunoACT, and antibody conjugates. The company maintains 15 development and manufacturing sites across Visakhapatnam, Bangalore, Kakinada, Hyderabad, and Mumbai in India, with additional facilities under expansion like a new CDMO R&D center in Genome Valley and microbial fermentation plants; it serves over 250 global clients including nine of the world's top 10 generic pharma companies, with exports to more than 60 countries spanning North America, Europe, Asia, and rest-of-world markets, supported by certifications from USFDA, WHO-Geneva, EMA, TGA, PMDA, MHRA, ANVISA, JAZMP, EDQM, and KFDA. Laurus Labs employs 7,042 people, including 2,634 in R&D and quality, across five R&D centers with 7,800 KL reactor volumes and capacity for over 10 billion oral solid dosage units annually; its subsidiaries include Laurus Bio for biologics and fermentation, Laurus Generics GmbH and Inc. for European and US generics distribution, and Laurus Synthesis for small-molecule CDMO. Recent developments include FY2025 revenues of Rs 5,554 crore with 20.1% EBITDA margins, a 42% rise in CDMO revenues to Rs 1,534 crore driven by small-molecule deliveries and new commercial-scale peptide synthesis, inauguration of a 200,000 sqft CDMO-focused R&D facility in September 2024, successful USFDA audits with EIR issuance for multiple sites, cumulative Rs 215 crore investment in joint venture KRKA Pharma (49% stake) for a high-potent oncology FDF facility in Hyderabad with groundbreaking planned for June 2025, Rs 120 crore equity infusion into Laurus Bio from Eight Roads Ventures and F-Prime Capital to expand fermentation capacity by 2026, ImmunoACT treating 300 patients with 73% response rate in relapsed/refractory B-cell lymphoma and initiating pediatric trials plus BCMA CAR-T Phase 1, Rs 659 crore capex primarily for CDMO growth including Vizag expansions and gene therapy GMP in Hyderabad by March 2026, and enhanced ESG standing with S&P Global Sustainability Yearbook 2025 inclusion as pharma "Industry Mover," DJSI score of 73, and 26MW renewable energy deal.